注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

The Lancet-Oncology(Jul 11,2016)  

2016-07-12 13:41:26|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
Jul 11, 2016
Weekly Features:
Gustoimages/Science Photo Library
Research | Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3)
The PORTEC-3 trial investigated the benefit of adjuvant chemoradiotherapy compared with radiotherapy alone for women with high-risk endometrial cancer.
Read this Article →
New journal
Introducing The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology covers all aspects of gastroenterology and hepatology. Following in The Lancet tradition, each monthly issue will feature original clinical research, expert reviews, news, and provocative comment and opinion to provide a clear, independent perspective of the clinical advances and practice-changing research shaping your field.
Submit your manuscript online →
Online First:
Dr E Walker/Science Photo Library
NEWS
Pembrolizumab for classical Hodgkin's lymphoma
The anti-PD-1 antibody pembrolizumab is effective in treating patients with classical Hodgkin's lymphoma, according to newly published research by Philippe Armand (Dana-Farber Cancer Institute, Boston, MA, USA) and colleagues.
Read this Report →
NEWS
BRCA mutations and risk of uterine cancer
Women who carry the BRCA gene mutation that increases their risk of breast and ovarian cancers might also be at higher risk of developing an aggressive form of uterine cancer, suggests new research by Catherine Shu (Columbia University Medical Center, New York, NY, USA) and colleagues.
Read this Report →
Katherine Gourd
NEWS
ESMO World Congress on Gastrointestinal Cancer 2016
News in Brief from the 18th European Society for Medical Oncology World Congress on Gastrointestinal Cancer, which was held on 29 June–2 July 2016 in Barcelona, Spain.
Read this Report →
CNRI/Science Photo Library
COMMENT
Early treatment for high-risk smouldering myeloma: has the time come?
Heinz Ludwig comments on the the long-term follow-up results of the QuiRedex trial.
Read this Comment →
ARTICLES
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial
Long-term follow-up results of the QuiRedex study, which compared early treatment with lenalidomide plus dexamethasone with observation in patients with high-risk smouldering multiple myeloma.
Read this Article →
Steve Gschmeissner/Science Photo Library
COMMENT
A prognostically relevant miRNA signature for epithelial ovarian cancer
Daniel Cramer and Kevin Elias comment on Marina Bagnoli and colleagues' study investigating miRNA tissue expression for its prognostic ability.
Read this Comment →
ARTICLES
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
This study aimed to develop a microRNA (miRNA)-based molecular classifier that can predict risk of progression or relapse in patients with epithelial ovarian cancer.
Read this Article →
Gustoimages/Science Photo Library
COMMENT
Combined modality adjuvant therapy for high-risk endometrial cancer
Adriaan Vanderstichele, Patrick Neven, and Ignace Vergote comment on the first results of the multicentre PORTEC-3 randomised trial.
Read this Comment →
ARTICLES
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
The PORTEC-3 trial investigated the benefit of adjuvant chemoradiotherapy compared with radiotherapy alone for women with high-risk endometrial cancer.
Read this Article →
Announcements:
Stay Connected
Stay Connected
If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

Follow us on Twitter
For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
The Lancet Choice
Access 5 articles from The Lancet Clinic for just $49.00
The Lancet Choice is a new payment option that gives you the freedom to access 5 premium articles of your choice from The Lancet Clinic's ever-growing collection of disease pages - all for the reduced introductory rate of $49.00.
Find out more →
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
  评论这张
 
阅读(6)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017